1. An NOX4 inhibitor for use in preventing and / or treating dysfunction of osteoclastogenesis and / or osteoporosis. 2. The NOX4 inhibitor according to claim 1, wherein the NOX4 inhibitor presents an inhibitory constant (Ki) for NOX4 inhibitory activity ranging from about 10 nm or less to 500 nm in a functional analysis of ROS production. The NOX4 inhibitor according to claim 1 for the prevention and / or treatment of osteoporosis. 4. The NOX4 inhibitor according to claim 1 for the prevention and / or treatment of dysfunction of osteoporotic and pre-osteoporotic osteoclastogenesis. 5. The NOX4 inhibitor according to claim 1 for use in the prevention and / or treatment of bone resorption of a secondary cause selected from Paget's disease, bone loss due to immobilization, osteolytic metastasis in bone tissue and bone tumors. 6. The NOX4 inhibitor according to claim 1 for use in the prevention and / or treatment of erosive joint destruction, diabetes mellitus osteoarthropathy, bone metastases, root resorption or eruptions in primary teeth, secondary hyperparathyroidism with loss of bone mass and bone atrophy due to inaction. . An NOX4 inhibitor selected from the following group: 4- (2-fluoro-4-methoxyphenyl) -2- (2-methoxyphenyl) -5- (pyridin-3-ylmethyl) -1H-pyrazolo [4,3-c] pyridin- 3.6 (2H, 5H) -dione； 2- (2-chlorophenyl) -4- (4-methoxyphenyl) -5- (pyrazin-2-ylmethyl) -1H-pyrazolo [4,3-c] pyridin-3 6 (2H, 5H) -dione； 4- (4-chlorophenyl) -2- (2-methoxyphenyl) -5- (pyrazin-2-ylmethyl) -1H-pyrazolo [4,3-c] pyridin-3, 6 (2H, 5H) -dione； 2- (2-chlorophenyl) -4- (2-fluoro-4-methoxyphenyl) -5 - [(1-methyl-1H-pyrazol-3-yl) methyl] -1H- pyrazolo [4,3-c] pyridin-3,6 (2H, 5H) -dione； 4- (2-fluoro-5-methoxyphenyl) -2- (2-methoxyphenyl) -5- (pyridin-3-ylmethyl) -1H-pyrazolo [4,3-c] pyridin-3,6 (2H, 5H) -dione； 2- (2-chlorophenyl) -5 - [(2-methoxypyridin-4-yl) methyl] -4-methyl -1H-pyrazolo [4,3-c] pyridin-3,6 (21. Ингибитор NOX4 для применения с целью предупреждения и/или лечени
